The bone densitometer market size is expected to advance at a CAGR of 4.7% during 2024–2030, to reach USD 441.3 million by 2030. This can be ascribed to the growing aging population, the rising cases of bone-related issues such as osteoarthritis, the increasing technological advancements, and the surging healthcare spending.
Osteoporosis is a progressive silent disease caused mainly in the geriatric population and menopausal women. Women are more affected as compared to men and this is a serious public health concern. Over 200 million people are estimated to be affected by osteoporosis across the world. The growing older population is contributing to an increase in cases of osteoporosis and other bone-related issues.
For instance, one-tenth of 60-year-old women, one-fifth of 70-year-old women, two-fifths of 80-year-old women, and actually two-thirds of 90-year-old women are suffered from this disease. Also, after the age of 50 years, one in three women in the world likely suffers an osteoporotic fracture. When a woman goes through menopause, the loss of estrogen affects her significantly more than it does a man of a similar age.
Moreover, in Europe, after ischemic heart disease, dementia, and lung cancer, fragility fractures are the fourth most common cause; nevertheless, they outrank ischemic stroke and chronic obstructive pulmonary disease. Around 10–20% of formerly community-dwelling individuals need long-term nursing care after suffering a hip fracture.
Overall, hip fractures are the most common cause of morbidity, and reported fatality rates in the first year after a hip fracture are up to 20–24%. Significant function and independence losses affect survivors, with 40% unable to walk without assistance and 60% needing it a year later. Thus, the increasing prevalence of osteoporosis will increase the demand for diagnostic procedures, which, in turn, will boost the market demand.
The APAC market is expected to witness the fastest growth, advancing at a CAGR of 5.2%, over the coming years. This can be attributed to the growing geriatric population, the rising awareness about osteoporosis, and the increasing healthcare expenditure in the region.
Among APAC countries, China holds a major market share, owing to the rising number of fractures, poor dietary habits, advancing technology, growing awareness about bone-related diseases among patients, government initiatives taken for the treatment of such diseases, and the introduction of advanced drugs. For instance, in December 2021, Ping An Healthcare and Technology Company and Chugai Pharma China introduced a whole course management system for osteoporosis patients. The collaboration was meant to increase the accessibility to quality innovative drugs and benefit osteoporosis patients.
Furthermore, the European market is expected to show considerable growth in the coming years. This can be attributed to the increasing female aging population, the rising healthcare expenditure and investment in R&D for the development of various treatments and drugs, and the surging cases of fatal osteoporosis-related fractures in the region. For instance, more than 23 million men and women in the European Union are at high risk of osteoporotic fractures. Also, hip or spine fractures are the primary cause of about a quarter of a million deaths in Europe each year. Thus, the increasing number of osteoporotic patients in the region is expected to propel the demand for bone densitometers.
The most-significant bone densitometer market players are GE Healthcare Technologies Inc., Hologic Inc., Swissray International Inc., DMS Imaging, Echolight S.p.a, and BeamMed Ltd.